BTRX-246040, also known as LY-2940094, is a potent and selective nociceptin receptor antagonist which is under development by BlackThorn Therapeutics and Eli Lilly for the treatment of major depressive disorder (MDD).

[1][2][3] It has demonstrated proof-of-concept clinical efficacy for depression.

[4] As of 2017, it is in phase II clinical trials for the treatment of MDD.

[1][2][3] It was also under investigation for the treatment of alcoholism, and similarly reached phase II clinical studies for this indication, but development was discontinued.

[1] This drug article relating to the nervous system is a stub.